🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Sun Pharma Advanced Research Company Limited SPARC NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://sparc.life
Company Profile ↓
₹179.27
+26.34% 1Y
Mkt Cap₹5,817.70 Cr
P/E3.67
P/B4.50
52W High₹277.57
52W Low₹108.71
Book Value₹41.26
EPS (TTM)₹48.81

Company Overview

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 116.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 111.8%.

Consistent Profit Growth

Net profit has compounded at 265.9% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 3.7, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 83.0%.

Recent Developments

  • Mar 2026 Revenue of ₹39.15 Cr (-45.5% YoY); net profit ₹1,553.20 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +314.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR -45.3%, profit CAGR 265.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-45.27%
1 Year:314.10%

Compounded Profit Growth

5 Years:265.94%
1 Year:-

Stock Price Performance

1 Year:+26.34%
6 Months:+22.19%
3 Months:-16.42%
1 Month:-8.58%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 42% of range
₹108.71 ₹277.57
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)35.82 · Neutral
Price Performance
1M-8.58%
3M-16.42%
6M+22.19%
1Y+26.34%
Valuation vs Sector

P/E of 3.67 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 116.0%.
  • Healthy ROCE of 111.8%.
  • Excellent profit margin of 83.0%.
  • Profit CAGR of 265.9% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -45.3% CAGR over 5 years.
  • Trading 35.4% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
3.67
Industry PE
36.43
Forward P/E
3.24
PEG Ratio
-
Book Value
₹41.26
Price to Book
4.50
P/S
3.15
EV/EBITDA
4.09
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-45.27%
Profit 5Y
265.94%
Revenue (YoY)
314.10%
Earnings (YoY)
-

Profitability & Returns

ROCE
111.85%
ROE
116.01%
ROA
71.55%
Profit Margin
82.97%
Op Margin
-90.68%
Gross Margin
98.30%
EPS (Latest Qtr)
₹54.27
EPS (TTM)
₹48.81

Balance Sheet & Liquidity

Debt/Equity
0.42
Quick Ratio
0.01
Current Ratio
2.47
Debt
₹559.31 Cr
Total Assets
₹2,170.88 Cr
Current Assets
₹1,862.43 Cr
Working Capital
₹1,108.32 Cr

Ownership

Promoter Holding
72.96%
Chg in Prom Hold
-2.16%
FII / Inst Holding
1.82%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹5,817.70 Cr
Total Revenue (TTM)
₹1,909.45 Cr
EBITDA
₹1,625.19 Cr
Free Cash Flow
₹-262.61 Cr
Operating Cash Flow
₹-238.78 Cr
Shares Outstanding
₹32.45 Cr
Gross Margin
98.30%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SPARC Sun Pharma Advanced Research Company Limited NSEPHARMA 179.27 3.67 ₹5,817.70 Cr 0.00% 111.85% 116.01% -45.27% 265.94%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 48.00 Cr24.00 Cr21.00 Cr14.00 Cr17.00 Cr17.00 Cr13.00 Cr-27.19 Cr9.64 Cr7.86 Cr8.45 Cr1,853.22 Cr
Cost of Revenue --------17.18 Cr10.67 Cr14.11 Cr13.48 Cr8.00 Cr
Gross Profit --------10.01 Cr-1.03 Cr-6.25 Cr-5.03 Cr1,845.22 Cr
Operating Expenses 137.00 Cr126.00 Cr113.00 Cr116.00 Cr122.00 Cr110.00 Cr116.00 Cr-66.14 Cr53.73 Cr62.03 Cr54.18 Cr74.42 Cr
Operating Income -93.00 Cr-105.00 Cr-94.00 Cr-106.00 Cr-109.00 Cr-96.00 Cr-106.00 Cr--56.13 Cr-54.76 Cr-68.28 Cr-59.21 Cr1,770.80 Cr
EBITDA -90.00 Cr-102.00 Cr-91.00 Cr-103.00 Cr-106.00 Cr-93.00 Cr-103.00 Cr--53.18 Cr-42.94 Cr-65.71 Cr-69.00 Cr1,775.00 Cr
Interest Expense 00001.00 Cr1.00 Cr1.00 Cr-4.54 Cr6.19 Cr7.52 Cr8.78 Cr11.64 Cr
Pretax Income -82.00 Cr-95.00 Cr-86.00 Cr-100.00 Cr-105.00 Cr-96.00 Cr-107.00 Cr--60.67 Cr-51.81 Cr-75.79 Cr-80.35 Cr1,760.96 Cr
Tax Provision -0-0-0-0-0-0-0--90.00 L6.00 L6.00 L7.00 L-38.00 L
Net Income -82.00 Cr-95.00 Cr-86.00 Cr-100.00 Cr-106.00 Cr-96.00 Cr-107.00 Cr--59.77 Cr-51.87 Cr-75.85 Cr-80.42 Cr1,761.34 Cr
Diluted EPS -2.53-2.94-2.66-3.07-3.26-2.96-3.31--1.84-1.60-2.34-2.4854.27

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -238.78 Cr75.55 Cr71.77 Cr39.15 Cr
Cost of Revenue -176.74 Cr135.79 Cr109.96 Cr51.39 Cr
Gross Profit -62.04 Cr-60.24 Cr-38.19 Cr-12.24 Cr
Operating Expenses -285.69 Cr351.26 Cr295.87 Cr-1,611.17 Cr
Operating Income --223.64 Cr-411.50 Cr-334.06 Cr1,598.93 Cr
EBITDA --203.18 Cr-373.13 Cr-321.85 Cr1,594.81 Cr
Interest Expense -7.63 Cr1.19 Cr8.54 Cr31.59 Cr
Pretax Income --222.58 Cr-386.83 Cr-342.78 Cr1,553.01 Cr
Tax Provision -038.20 L-27.18 L-19.44 L
Net Income --222.58 Cr-387.21 Cr-342.51 Cr1,553.20 Cr
Diluted EPS --7.82-11.93-10.5547.86

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -830.13 Cr515.04 Cr335.53 Cr2,170.88 Cr
Current Assets -454.96 Cr269.39 Cr26.20 Cr1,862.43 Cr
Cash & Equivalents -58.36 L5.33 Cr1.96 Cr1.16 Cr
Inventory -----
Receivables -32.71 Cr15.53 Cr16.06 Cr8.27 Cr
Total Liabilities -317.35 Cr389.29 Cr552.48 Cr832.05 Cr
Current Liabilities -178.95 Cr265.06 Cr374.24 Cr754.11 Cr
Long Term Debt 0-0100.00 Cr0
Total Debt -15.68 Cr57.66 Cr265.13 Cr557.80 Cr
Total Equity -512.78 Cr125.76 Cr-216.95 Cr1,338.83 Cr
Shares Outstanding -32.45 Cr32.45 Cr32.45 Cr32.45 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --69.12 Cr-429.19 Cr-360.29 Cr-238.78 Cr
Investing Cash Flow --548.28 Cr391.53 Cr157.66 Cr-23.50 Cr
Financing Cash Flow -616.76 Cr42.41 Cr199.26 Cr261.39 Cr
Capital Expenditure --15.39 Cr-26.51 Cr-10.34 Cr-23.83 Cr
Free Cash Flow --84.50 Cr-455.70 Cr-370.63 Cr-262.61 Cr
Net Change in Cash --64.06 L4.74 Cr-3.38 Cr-88.73 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -26.0%-79.7%-53.2%-31.3%
Operating Margin % --93.7%-544.7%-465.5%4,084.3%
Net Margin % --93.2%-512.6%-477.3%3,967.5%
ROE % --43.4%-307.9%157.9%116.0%
ROCE % --34.3%-164.6%863.1%112.9%

Shareholding Pattern

Insiders
72.96%
Institutions
1.82%
Public Float
6.75%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SPARC

Google News ue, 20 Oct 2026

SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE5tV2pramlZUG1hLTN6czY3bjkxOGZrbTFMdjhWZzZyRVhEdTBxcFZER2lMWjF6YUdMaXhoalhKMUhRNFRGS3JxOXJiQ19aVmhBdFE?oc=5" target="_blank">SciSparc Ltd. (SPRC) stock price, news, quote and histor…

Google News Mon, 19 Oct 2026

Sun Pharma Advanced Research Company Stock Price Forecast. Should You Buy SPARC.NS? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTFA2UmFqRUEwdmNfT242X1hQaWVKRTJ2OFRzYTUxUVFfbTItX09vM2ZvbEtjYjQzZFRsWEczUU1MS1FiU2lZaFJ0MnNDUm9oUQ?oc=5" target="_blank">Sun Pharma Advanced Research Company Stock Price Forecast. Sh…

Google News ue, 20 Oct 2026

SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE00SU5nem41N0pDdG04QVhvMWNkcmNjUUpUODhNUGVNRWF6OExEQWJ3d3NyS0djdF9MWnN5NjJyYWR2UGVjZWhKRXBBczVwQmNJUUE?oc=5" target="_blank">SciSparc Ltd. (SPRC) Stock Price, News, Quote & History<…

Google News Sat, 17 Oct 2026

SPARC Shares Surge Nearly 8% On Licensing Pact With Sun Pharma - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQTkN1ZllvU0NhamFrd0w3U2p5eGVUajUzM3dKMEtzem5ycHl4T1N1YmV6QzRhMXJnWHlPMTlCeGlaOFp6dWZzdlVYcThvSFdaYlhuMkJpdEN1M2w1QmE4aGctSFc1SFROX0xYc1F5SnI0VzFqUTJJYktvQkc3X05BVFRwSDNVSnVuanVTSW…

Google News Wed, 08 Apr 2026

Universal Music: Pershing Square Offer Highlights Company Value and Trades Cash for Dilution - Morningstar

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZjNVVlh5SzNhd0l6eFpDc0lvY2xybzJFT0RhRHltendtMVJRRjRQN3ZWOTcydUY4UUNFSUNoOU00X0RZOVZxQldKN3Nvb2ZobmU4N3ZEV0w3X2I3bVh6M1UxQ3BidHZ6bEViTFp1Sy01MzJuNUdXWEg0bTJSQmhzSnQ0MVFXV3A1UXF1WG…

Google News Wed, 21 Oct 2026

Why Did Sparc Technologies Limited (ASX:SPN) Shares Drop Today? - Kalkine

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOV0o2QjFVV09TYlV2VDdnaUtpWXBHOHBMaEZTVTV3cjBLejdhQW1LLXdBc1FoekloRXZrcnpDcUUzcnVhdWhvQ2d2UUdYc3BFcG8taHF5SVpSTXEzbkZOQzRwRGU4X2lMcWtDd3BuWjg3VzgxanV1eVZ6S1BiSTlCWFNKalN2YlVaN2RhVE…

SPARC — Frequently Asked Questions

What is the current share price of Sun Pharma Advanced Research Company Limited (SPARC)?

As of 2026-10-23 04:58 IST, Sun Pharma Advanced Research Company Limited (SPARC) trades at ₹179.27 on NSE. Its 52-week range is ₹108.71 to ₹277.57.

What is the market capitalisation of SPARC?

Sun Pharma Advanced Research Company Limited (SPARC) has a market capitalisation of ₹5,817.70 Cr on NSE.

What is the P/E ratio of SPARC?

SPARC trades at a trailing price-to-earnings (P/E) ratio of 3.67. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 4.50.

What is the return on equity (ROE) of SPARC?

SPARC has a return on equity (ROE) of 116.01%. Its return on capital employed (ROCE) is 111.85%.

Is SPARC a good stock to buy?

This page provides a data-driven analysis of Sun Pharma Advanced Research Company Limited (SPARC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space